A Phase II Trial of Adjuvant Chemotherapy With S-1 Plus Oxaliplatin for Locally Advanced Gastric Cancer
Status:
Terminated
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
Patients with advanced gastric cancer have showed poor prognosis. Only 81% of the patients
could underwent curative surgery. In those, about 60% of patients would survive after 5 years
from the surgery. As a result, role of chemotherapy has been increased. In ACTS-GC trial, S-1
adjuvant therapy after D2 gastrectomy increased overall survival rate in advanced gastric
cancer patients. However, subgroup analysis showed that S-1 adjuvant therapy was insufficient
in patients with stage III or IV (according to the AJCC 6th criteria) gastric cancer. In
addition, CLASSIC trial demonstrated that oxaliplatin plus capecitabine adjuvant therapy
could increase disease-free survival after D2 gastrectomy in advanced gastric cancer
patients. Notwithstanding these trial, optimal adjuvant regimen of advanced gastric cancer
has not been established. We aimed to evaluate efficacy of S-1 plus oxaliplatin as adjuvant
chemotherapy after D2 gastrectomy in stage III (according to the AJCC 7th criteria) gastric
cancer patients.